A combination of two existing skin cancer drugs and a third experimental drug could lead to a new strategy for treating patients who do not respond to existing therapies, a new study in mice suggests.

Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours.